HIV/AIDS and bone: an unrecognised threat?

References

• Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. 2012 [cited 2013 August 28]. Available from: http://www.unaids.org/en/dataanalysis/knowyourepidemic/2012
   Google Scholar
• Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV medicine. 2012;13(8):453–68. Epub 2012/03/15.
   PubMed Web of Science ®Google Scholar
• Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187–94. Epub 2008/04/26.10.1002/(ISSN)1097-0215
   PubMed Web of Science ®Google Scholar
• Galli L, Salpietro S, Pellicciotta G, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27(8):657–665. Epub 2012/06/23.10.1007/s10654-012-9707-5
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74. Epub 2006/11/07.10.1097/QAD.0b013e32801022eb
   PubMed Web of Science ®Google Scholar
• Meintjes G, Boulle A, et al. Guidelines for antiretroviral therapy in adults. S Afr J HIV Med. 2012;13(3):114–33.
   Web of Science ®Google Scholar
• Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFα activation. J Med Virol. 2008;80(9):1507–14. Epub 2008/07/24.10.1002/jmv.v80:9
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Daniels B, Gunawardene S, et al. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14. Epub 2008/12/26.10.1089/aid.2008.0183
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–801. Epub 2011/05/25.10.1093/infdis/jir188
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5):S505–11. Epub 1995/11/01.10.1016/8756-3282(95)00258-4
   PubMed Web of Science ®Google Scholar
• Shisana ORT, Simbayi LC, Zuma K, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers? HSRC Press; 2009.
   Google Scholar
• Hamill MM, Ward KA, PettiforJM, et al. Bone mass, body composition and vitamin D status of ARV-naive, urban, black South African women with HIV infection, stratified by CD count. Osteoporos Int. 2013;24:2855–61. Epub 2013/05/31.
   Google Scholar
• Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19(3):402–9. Epub 2004/03/26.
   PubMed Web of Science ®Google Scholar
• Staa TP, Staa T. P. van, Staa T. P. van. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87. Epub 2002/10/16.10.1007/s001980200108
   PubMed Web of Science ®Google Scholar
• Cournil A, Eymard-Duvernay S, Diouf A, et al. Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in senegal. PLoS ONE. 2012;7(2):e31726. Epub 2012/02/24.10.1371/journal.pone.0031726
   Google Scholar
• Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir df in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1—infected patients. HIV Clin Trials. 2007;8(3):164–72. Epub 2007/07/11.10.1310/hct0803-164
   PubMed Web of Science ®Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10(8):482–7. Epub 2009/05/23.10.1111/hiv.2009.10.issue-8
   PubMed Web of Science ®Google Scholar
• Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005;6(5):341–6. Epub 2005/09/15.10.1111/hiv.2005.6.issue-5
   PubMed Web of Science ®Google Scholar
• Klassen K, Martineau AR, Wilkinson RJ et al. The Effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS ONE. 2012;7(9):e44845. Epub 2012/09/18.10.1371/journal.pone.0044845
   Google Scholar
• Masiá M, Padilla S, Robledano C, et al. Short communication: early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2012;28(3):242–6. Epub 2011/06/07.10.1089/aid.2011.0052
   PubMed Web of Science ®Google Scholar
• Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun. 2010;394(1):48–53. Epub 2010/02/23.10.1016/j.bbrc.2010.02.080
   PubMed Web of Science ®Google Scholar
• Grigsby IF, Pham L, Gopalakrishnan R, et al. Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun. 2010;391(3):1324–1329. Epub 2009/12/23.10.1016/j.bbrc.2009.12.039
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta‐analysis: renal safety of tenofovir disoproxil fumarate in hiv‐infected patients. Clin Infect Dis. 2010;51(5):496–505. Epub 2010/08/03.10.1086/652979
   PubMed Web of Science ®Google Scholar
• Landriscina M, Altamura SA, Roca L, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer. 2008;122(12):2842–50. Epub 2008/03/21.10.1002/(ISSN)1097-0215
   PubMed Web of Science ®Google Scholar
• Pan G, Kilby M, McDonald JM. Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses. 2006;22(11):1131–41. Epub 2006/12/07.10.1089/aid.2006.22.1131
   PubMed Web of Science ®Google Scholar
• Pan G, Wu X, McKenna MA, et al. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20(6):608–20. Epub 2004/07/10.10.1089/0889222041217482
   PubMed Web of Science ®Google Scholar
• Pan G, Yang Z, Ballinger SW, et al. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci. 2006;1068:297–308. Epub 2006/07/13.10.1196/annals.1346.057
   PubMed Web of Science ®Google Scholar
• Hansen AB, Gerstoft J, Kronborg Get al. Incidence of low and high-energy fractures in persons with and without HIV infection. AIDS. 2012;26(3):285–93. Epub 2011/11/19.10.1097/QAD.0b013e32834ed8a7
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–6. Epub 2011/10/15.10.1093/cid/cir627
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52(8):1061–8. Epub 2011/03/15.10.1093/cid/ciq242
   PubMed Web of Science ®Google Scholar
• Crotti TN, Smith MD, Findlay DM, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials. 2004;25(4):565–73. Epub 2003/11/11.
   PubMed Web of Science ®Google Scholar
• Vikulina T, Fan X, Yamaguchi M, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci. 2010;107(31):13848–53. Epub 2010/07/21.10.1073/pnas.1003020107
   PubMed Web of Science ®Google Scholar
• Barkhordarian A, Ajaj R, Ramchandani MH, et al. Osteoimmunopathology in HIV/AIDS: a translational evidence-based perspective. Pathol Res Int. 2011;2011:359242. Epub 2011/06/11.
   PubMedGoogle Scholar
• Cotter EJ, Chew N, Powderly WG. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. AIDS Res Hum Retroviruses. 2011;27(2):187–99. Epub 2010/10/12.10.1089/aid.2010.0114
   PubMed Web of Science ®Google Scholar
• Hough SA-E, Brown S, Cassim B, et al. NOFSA guideline for the diagnosis and management of osteoporosis. JEMDSA. 2010;15(3):107–8.
   Google Scholar
• Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s health initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. Epub 2011/04/21.10.1136/bmj.d2040
   PubMed Web of Science ®Google Scholar
• Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr. 2011;57(3):197–204. Epub 2011/04/08.10.1097/QAI.0b013e31821ae418
   PubMed Web of Science ®Google Scholar
• Schnitzler CM, Mesquita JM. Cortical bone histomorphometry of the iliac crest in normal black and white South African adults. Calcif Tissue Int. 2006;79(6):373–82. Epub 2006/12/13.10.1007/s00223-006-0053-z
   PubMed Web of Science ®Google Scholar
• Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426–31. Epub 2005/03/15.10.1097/01.qai.0000145352.04440.1e
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey A, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab. 2012;97(6):1922–8. Epub 2012/03/16.10.1210/jc.2012-1424
   PubMed Web of Science ®Google Scholar